What is the recommended management, including drug choices and dosing, for uncomplicated and severe malaria in children?

Management of Malaria in Paediatric Patients

For uncomplicated malaria in children, use oral artemisinin-based combination therapy (ACT) as first-line treatment; for severe malaria, administer intravenous artesunate at 3 mg/kg (not the lower FDA-suggested 2.4 mg/kg dose). 1, 2, 3

Diagnostic Approach

Before initiating treatment, confirm malaria parasitologically with:

• Thick blood smear (or rapid diagnostic test) PLUS thin blood film
• Alternative: Rapid antigen detection test paired with thin blood film

Key clinical pearl: Thrombocytopenia in a febrile child returning from endemic areas is highly predictive of malaria and should trigger immediate testing 3.

Exception: In suspected severe cases where testing is not immediately feasible, begin treatment empirically 1.

Uncomplicated Malaria Treatment

P. falciparum (First-line: ACT)

Artemether-lumefantrine (Riamet/Coartem) - Given at 0,8,24,36,48, and 60 hours:

• 5 to <15 kg: 1 tablet per dose
• 15 to <25 kg: 2 tablets per dose
• 25 to <35 kg: 3 tablets per dose
• ≥35 kg: 4 tablets per dose 4

Alternative ACT option: Artenimol-piperaquine 3

Second-line alternatives when ACT unavailable:

• Atovaquone-proguanil (Malarone) for 3 days:

  • 5-8 kg: 2 paediatric tablets (25 mg)
  • 9-10 kg: 3 paediatric tablets
  • 11-20 kg: 1 adult tablet (100 mg)
  • 21-30 kg: 2 adult tablets
  • 31-40 kg: 3 adult tablets

  • 40 kg: 4 adult tablets 4

• Mefloquine: 15 mg base/kg followed by 10 mg/kg 8-24 hours later 4

Non-falciparum Malaria (P. vivax, P. ovale, P. malariae)

• Chloroquine OR ACT 3, 5
• Note: ACT is effective even for chloroquine-resistant P. vivax 5

Severe Malaria Treatment

Intravenous artesunate is superior to quinine and must be used as first-line therapy 1, 3, 5. This applies to all Plasmodium species, all trimesters of pregnancy, and all children.

Artesunate Dosing - Critical Consideration

Use 3 mg/kg IV, NOT 2.4 mg/kg 2. Recent pharmacokinetic evidence demonstrates that younger children (<20 kg) given the lower 2.4 mg/kg dose do not achieve adequate drug exposures compared to older children. The FDA's lower dose recommendation should be withdrawn, as artesunate is extremely safe and underdosing poses harm in this rapidly lethal infection 2.

Alternative When Artesunate Unavailable or Contraindicated

Quinine hydrochloride:

• Loading dose: 20 mg salt/kg IV over 4 hours
• Maintenance: 10 mg/kg IV over 4 hours, every 8 hours
• Continue for 7 days OR switch to oral therapy once tolerated (complete full course with ACT, mefloquine, or atovaquone-proguanil) 4

Critical caveat: Omit quinine loading dose if patient received mefloquine prophylaxis in previous 24 hours or treatment dose within 3 days 4.

Avoid oral quinine in children - bitter taste severely affects compliance 4.

Management of Severe Malaria Complications

Seizure Management Algorithm

Seizures occur in 25% of severe malaria cases; some are subtle (eye deviation, irregular breathing, drooling) 4.

Immediate actions:

1. High-flow oxygen
2. Check glucose (hypoglycemia precipitates seizures)
3. Establish vascular or intraosseous access

Sequential anticonvulsant therapy:

• Lorazepam 0.1 mg/kg IV/IO (repeat once if >10 minutes)
• If persistent: Paraldehyde 0.4 mg/kg rectally (0.8 ml/kg prepared solution)
• If still uncontrolled: Phenytoin 18 mg/kg IV over 20 minutes OR Phenobarbital 15-20 mg/kg IV over 10 minutes
• If refractory: Call anesthetist for rapid sequence intubation with Thiopental 4 mg/kg IV 4

Do NOT use prophylactic anticonvulsants - prophylactic phenobarbital increased mortality in African children with cerebral malaria, particularly when combined with diazepam (likely from respiratory depression) 4.

Airway and Respiratory Management

• Initiate high-flow oxygen immediately
• Features of raised intracranial pressure warrant elective intubation and ventilation
• For postictal children: delay ventilation if airway patent and respiration adequate
• Optimize PCO₂ in normal range - no evidence that hyperventilation benefits raised intracranial pressure 4

Special Populations

Neonates (≤28 days)

The evidence for neonatal malaria management is extremely sparse 6. Current practice shows:

• Most neonates are initially misdiagnosed with sepsis (70%)
• Treatment regimens vary substantially and often deviate from standard recommendations
• Oral administration methods include syrup, crushed tablets, or orogastric tube
• Apply standard pediatric dosing with close monitoring until specific neonatal guidelines are developed

Common Pitfalls to Avoid

1. Underdosing artesunate in young children - use 3 mg/kg, not 2.4 mg/kg
2. Missing subtle seizures - look for eye deviation, irregular breathing, drooling
3. Prescribing oral quinine - poor compliance due to bitter taste
4. Using prophylactic anticonvulsants - increases mortality
5. Delaying parasitological confirmation - except in immediately life-threatening presentations
6. Forgetting to check glucose - hypoglycemia is common and treatable

Primaquine Considerations

• Single-dose gametocytocidal primaquine: G6PD testing NOT required 1
• Radical cure with primaquine or tafenoquine: G6PD testing ESSENTIAL before administration 1